ImmunoMet Therapeutics Receives IND Clearance and Orphan Drug Designation from U.S. FDA for IM156 in Ideopathic Pulmonary Fibrosis and Completes Financing
– Phase 1 clinical study recruitment in healthy volunteers is expected to start in Q1 2021 – – Pre-clinical studies…